WO2000029579A1 - Proteine de type chondromoduline de mammmifere - Google Patents

Proteine de type chondromoduline de mammmifere Download PDF

Info

Publication number
WO2000029579A1
WO2000029579A1 PCT/US1999/026909 US9926909W WO0029579A1 WO 2000029579 A1 WO2000029579 A1 WO 2000029579A1 US 9926909 W US9926909 W US 9926909W WO 0029579 A1 WO0029579 A1 WO 0029579A1
Authority
WO
WIPO (PCT)
Prior art keywords
zchml
polypeptide
cells
protein
polypeptides
Prior art date
Application number
PCT/US1999/026909
Other languages
English (en)
Inventor
Si Lok
Scott R. Presnell
Original Assignee
Zymogenetics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics, Inc. filed Critical Zymogenetics, Inc.
Priority to IL14305299A priority Critical patent/IL143052A0/xx
Priority to JP2000582562A priority patent/JP2002530078A/ja
Priority to CA002350623A priority patent/CA2350623A1/fr
Priority to EP99958955A priority patent/EP1131427A1/fr
Priority to AU16222/00A priority patent/AU1622200A/en
Publication of WO2000029579A1 publication Critical patent/WO2000029579A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor

Definitions

  • Chm- I The chondromodulin-I (Chm- I) is a factor described from bovine cartilage [Hiraki et al . BBRC, 175 : 971-977 (1991), Hiraki et al . J. Biol . Chem. 271 : 22657-22662 (1996). Chm- I
  • Bovine Chm- I Human and bovine Chm- I share a high degree of structural sequence conservation.
  • Bovine Chm- I is produced as a 335 amino acid precursor polypeptide with features common to the class II cell surface proteins. Most notably, the precursor polypeptide has a nonclassical leader sequence that is followed by a hydrophobic putative transmembrane domain (TMD) sequence. Proteolytic cleavage of the precursor polypeptide gives rise to a mature active protein consisting of the carboxyl-terminal 121 amino acid residues.
  • a processing signal (Arg-Glu-Arg-Arg, SEQ ID NO: 10) precedes the mature protein sequence.
  • Mature bovine and human Chm- I have two domains. One domain covers the amino-terminal half of the mature protein. The amino-domain is rather hydrophilic and contains all the potential glycosylation sites and exhibits less sequence conservation than the carboxy- terminal domain.
  • the carboxyl -terminal domain contains a hydrophobic region and eight cysteine residues. This domain is highly conserved in bovine and human Chm-I. The residues are 98% identical in this region.
  • the carboxyl - terminal domain of mature Chm-I has been shown to be highly proteinase resistant and is believed to be tightly folded, Neame et al . , J. Biol . Chem . 265 : 9628-9633
  • Bovine Chm-I transcripts are found only in cartilaginous tissues. High transcript levels are located in chondrocytes, especially abundant in cells in the proliferating cartilage zones, Hiraki et a-Z . , J. Biol . Chem . , 272 : 32419-32426 (1997). Chm-I expression is localized specifically to the avascular zones of cartilage in the developing bone and is not expressed in calcifying cartilage nor in bony or the surrounding soft tissues. Immunohistochemical study indicates Chm-I protein co- localizes with its transcript.
  • Chm-I has a number of bone and cartilage related biological activities. Chm-I has been shown to stimulate osteoblast proliferation, Mori et al . FEBS Lett . , 406: 310-314 (1997) . Bovine Chm-I is shown to stimulate DNA synthesis of culture growth-plate chondrocytes in the presence of basic fibroblast growth factor (FGF) , Hiraki et al . , BBRC, 175 : 971-977 (1991). It appears to function as an autocrine chondrocyte colony-stimulating factor, which synergizes with FGF-2 to stimulate colony formation of growth plate chondrocytes in agarose cultures, Inoue et al .
  • FGF basic fibroblast growth factor
  • Chm-I has been identified as an endothelial cell growth inhibitor, Hiraki et al . FEBS Lett, 415:321-324 (1997) and Hiraki et al . , J. Biol . Chem . , 272 : 32419-32426 (1997). This finding suggests that Chm-I has a regulatory role in vascular invasion during endochondral formation and the maintenance of avascularization in cartilage.
  • the present invention addresses this need by providing novel polypeptides and related compositions and methods.
  • the present invention provides an isolated polynucleotide encoding a mammalian chondromodulin-like protein termed Zchml .
  • the human Zchml polypeptide with signal sequence is comprised of a sequence of amino acids 317 amino acids long with the initial Met as shown in SEQ ID NO:l and SEQ ID NO: 2.
  • Amino acid residues 34-48 of SEQ ID NO: 2 may define a transmembrane domain, also defined by SEQ ID NO : 3.
  • An alternative transmembrane domain may be defined by amino acid residues 31-50 of SEQ ID NO: 2, also defined by SEQ ID NO:4.
  • the lysine residues at positions 213-214 indicate a likely cleavage site between amino acid residue 214, a lysine, and amino acid residue 215, a glycine. This would produce a mature Zchm-1 polypeptide extending from amino acid residue 215, a glycine through amino acid residue 317 of SEQ ID NO: 2, also define by SEQ ID NO: 5.
  • the mature sequence extends from amino acid residue 255, a phenylalanine, through amino acid residue 317 of SEQ ID NO : 2 , also defined by SEQ ID NO: 6.
  • Zchm-1 include a sequence extending from amino acid residue 202 through amino acid residue 311 of SEQ ID NO: 2 also defined by SEQ ID NO: 11, and the sequence extending from amino acid residue 48 through amino acid residue 311 of SEQ ID NO : 2 also defined by SEQ ID NO: 12.
  • an expression vector comprising (a) a transcription promoter; (b) a DNA segment encoding Zchml polypeptide, and (c) a transcription terminator, wherein the promoter, DNA segment, and terminator are operably linked.
  • a cultured eukaryotic cell into which has been introduced an expression vector as disclosed above, wherein said cell expresses a protein polypeptide encoded by the DNA segment .
  • a chimeric polypeptide consisting essentially of a first portion and a second portion joined by a peptide bond.
  • the first portion of the chimeric polypeptide consists essentially of (a) a Zchml polypeptide as shown in SEQ ID NO: 2 (b) allelic variants of SEQ ID NO: 2; and (c) protein polypeptides that are at least 99% identical to (a) or (b) .
  • the second portion of the chimeric polypeptide consists essentially of another polypeptide such as an affinity tag.
  • the affinity tag is an immunoglobulin F c polypeptide.
  • the invention also provides expression vectors encoding the chimeric polypeptides and host cells transfected to produce the chimeric polypeptides.
  • an antibody that specifically binds to a Zchml polypeptide as disclosed above, and also an anti-idiotypic antibody which neutralizes the antibody to a Zchml polypeptide .
  • An additional embodiment of the present invention relates to a peptide or polypeptide which has the amino acid sequence of an epitope-bearing portion of a Zchml polypeptide having an amino acid sequence described above.
  • Peptides or polypeptides having the amino acid sequence of an epitope-bearing portion of a Zchml polypeptide of the present invention include portions of such polypeptides with at least nine, preferably at least 15 and more preferably at least 30 to 50 amino acids, although epitope-bearing polypeptides of any length up to and including the entire amino acid sequence of a polypeptide of the present invention described above are also included in the present invention.
  • Examples of such polypeptides are polypeptides comprised of SEQ ID NOs : 2, 5, 6, 11, 12 and 16-22. Also claimed are any of these polypeptides that are fused to another polypeptide or carrier molecule.
  • affinity tag is used herein to denote a polypeptide segment that can be attached to a second polypeptide to provide for purification or detection of the second polypeptide or provide sites for attachment of the second polypeptide to a substrate.
  • affinity tag any peptide or protein for which an antibody or other specific binding agent is available can be used as an affinity tag.
  • Affinity tags include a poly-histidine tract, protein A, Nilsson et al . , EMBO J. 4:1075 (1985); Nilsson et al . ,
  • allelic variant is used herein to denote any of two or more alternative forms of a gene occupying the same chromosomal locus. Allelic variation arises naturally through mutation, and may result in phenotypic polymorphism within populations. Gene mutations can be silent (no change in the encoded polypeptide) or may encode polypeptides having altered amino acid sequence.
  • allelic variant is also used herein to denote a protein encoded by an allelic variant of a gene .
  • amino-terminal and carboxyl- terminal are used herein to denote positions within polypeptides. Where the context allows, these terms are used with reference to a particular sequence or portion of a polypeptide to denote proximity or relative position. For example, a certain sequence positioned carboxyl- terminal to a reference sequence within a polypeptide is located proximal to the carboxyl terminus of the reference sequence, but is not necessarily at the carboxyl terminus of the complete polypeptide.
  • complement/anti-complement pair denotes non-identical moieties that form a non-covalently associated, stable pair under appropriate conditions.
  • biotin and avidin are prototypical members of a complement/anti-complement pair.
  • Other exemplary complement/anti-complement pairs include receptor/ligand pairs, antibody/antigen (or hapten or epitope) pairs, sense/antisense polynucleotide pairs, and the like.
  • the complement/anti-complement pair preferably has a binding affinity of ⁇ 10 9 M" 1 .
  • polynucleotide molecule is a polynucleotide molecule having a complementary base sequence and reverse orientation as compared to a reference sequence.
  • sequence 5 ' ATGCACGGG 3 ' is complementary to 5 ' CCCGTGCAT 3 ' .
  • contig denotes a polynucleotide that has a contiguous stretch of identical or complementary sequence to another polynucleotide. Contiguous sequences are said to "overlap" a given stretch of polynucleotide sequence either in their entirety or along a partial stretch of the polynucleotide. For example, representative contigs to the polynucleotide sequence 5'- ATGGCTTAGCTT-3 ' are 5 ' -TAGCTTgagtct-3 ' and 3 ' - gtcgacTACCGA-5 ' .
  • degenerate nucleotide sequence denotes a sequence of nucleotides that includes one or more degenerate cod ⁇ ns (as compared to a reference polynucleotide molecule that encodes a polypeptide) .
  • Degenerate codons contain different triplets of nucleotides, but encode the same amino acid residue (i.e., GAU and GAC triplets each encode Asp) .
  • expression vector is used to denote a DNA molecule, linear or circular, that comprises a segment encoding a polypeptide of interest operably linked to additional segments that provide for its transcription.
  • additional segments include promoter and terminator sequences, and may also include one or more origins of replication, one or more selectable markers, an enhancer, a polyadenylation signal, etc.
  • Expression vectors are generally derived from plasmid or viral DNA, or may contain elements of both.
  • isolated when applied to a polynucleotide, denotes that the polynucleotide has been removed from its natural genetic milieu and is thus free of other extraneous or unwanted coding sequences, and is in a form suitable for use within genetically engineered protein production systems.
  • isolated molecules are those that are separated from their natural environment and include cDNA and genomic clones.
  • Isolated DNA molecules of the present invention are free of other genes with which they are ordinarily associated, but may include naturally occurring 5 ' and 3 ' untranslated regions such as promoters and terminators. The identification of associated regions will be evident to one of ordinary skill in the art (see for example, Dynan and Tijan, Nature 316 : 774 - 78 (1985) .
  • an "isolated" polypeptide or protein is a polypeptide or protein that is found in a condition other than its native environment, such as apart from blood and animal tissue.
  • the isolated polypeptide is substantially free of other polypeptides, particularly other polypeptides of animal origin. It is preferred to provide the polypeptides in a highly purified form, i.e. greater than 95% pure, more preferably greater than 99% pure.
  • the term “isolated” does not exclude the presence of the same polypeptide in alternative physical forms, such as dimers or alternatively glycosylated or derivatized forms.
  • DNA segments indicates that the segments are arranged so that they function in concert for their intended purposes, e . g. , transcription initiates in the promoter and proceeds through the coding segment to the terminator.
  • ortholog denotes a polypeptide or protein obtained from one species that is the functional counterpart of a polypeptide or protein from a different species. Sequence differences among orthologs are the result of speciation.
  • Parenters are distinct but structurally related proteins made by an organism. Paralogs are believed to arise through gene duplication. For example, a-globin, b- globin, and myoglobin are paralogs of each other.
  • polynucleotide is a single- or double- stranded polymer of deoxyribonucleotide or ribonucleotide bases read from the 5' to the 3' end.
  • Polynucleotides include RNA and DNA, and may be isolated from natural sources, synthesized in vi tro, or prepared from a combination of natural and synthetic molecules. Sizes of polynucleotides are expressed as base pairs (abbreviated "bp") , nucleotides ("nt”), or kilobases ("kb”). Where the context allows, the latter two terms may describe polynucleotides that are single-stranded or double- stranded.
  • a “polypeptide” is a polymer of amino acid residues joined by peptide bonds, whether produced naturally or synthetically. Polypeptides of less than about 10 amino acid residues are commonly referred to as “peptides” .
  • promoter is used herein for its art- recognized meaning to denote a portion of a gene containing DNA sequences that provide for the binding of RNA polymerase and initiation of transcription. Promoter sequences are commonly, but not always, found in the 5' non-coding regions of genes.
  • a “protein” is a macromolecule comprising one or more polypeptide chains.
  • a protein may also comprise non- peptidic components, such as carbohydrate groups. Carbohydrates and other non-peptidic substituents may be added to a protein by the cell in which the protein is produced, and will vary with the type of cell. Proteins are defined herein in terms of their amino acid backbone structures; substituents such as carbohydrate groups are generally not specified, but may be present nonetheless.
  • receptor denotes a cell-associated protein that binds to a bioactive molecule (i.e., a ligand) and mediates the effect of the ligand on the cell.
  • a bioactive molecule i.e., a ligand
  • Membrane-bound receptors are characterized by a multi- domain structure comprising an extracellular ligand- binding domain and an intracellular effector domain that is typically involved in signal transduction. Binding of ligand to receptor results in a conformational change in the receptor that causes an interaction between the effector domain and other molecule (s) in the cell. This interaction in turn leads to an alteration in the metabolism of the cell.
  • Metabolic events that are linked to receptor-ligand interactions include gene transcription, phosphorylation, dephosphorylation, increases in cyclic AMP production, mobilization of cellular calcium, mobilization of membrane lipids, cell adhesion, hydrolysis of inositol lipids and hydrolysis of phospholipids .
  • receptors can be membrane bound, cytosolic or nuclear; monomeric (e.g., thyroid stimulating hormone receptor, beta-adrenergic receptor) or multimeric ( e . g. , PDGF receptor, growth hormone receptor,
  • IL-3 receptor GM-CSF receptor, G-CSF receptor, erythropoietin receptor and IL-6 receptor
  • secretory signal sequence denotes a DNA sequence that encodes a polypeptide (a "secretory peptide") that, as a component of a larger polypeptide, directs the larger polypeptide through a secretory pathway of a cell in which it is synthesized.
  • the larger polypeptide is commonly cleaved to remove the secretory peptide during transit through the secretory pathway.
  • splice variant is used herein to denote alternative forms of RNA transcribed from a gene. Splice variation arises naturally through use of alternative splicing sites within a transcribed RNA molecule, or less commonly between separately transcribed RNA molecules, and may result in several mRNAs transcribed from the same gene. Splice variants may encode polypeptides having altered amino acid sequence. The term splice variant is also used herein to denote a protein encoded by a splice variant of an mRNA transcribed from a gene.
  • the present invention addresses this need by providing novel polypeptides and related compositions and methods.
  • the present invention provides an isolated polynucleotide encoding a mammalian chondromodulin-like protein termed Zchml.
  • the human Zchml polypeptide with signal sequence is comprised of a sequence of amino acids 317 amino acids long with the initial Met as shown in SEQ ID NO:l and SEQ ID NO: 2.
  • Amino acid residues 34-48 of SEQ ID NO: 2 may define a transmembrane domain, also defined by SEQ ID NO: 3.
  • An alternative transmembrane domain may be defined by amino acid residues 31-50 of SEQ ID NO: 2, also defined by SEQ ID NO : 4.
  • the lysine residues at positions 213-214 indicate a likely cleavage site between amino acid residue 214, a lysine, and amino acid residue 215, a glycine.
  • the mature sequence extends from amino acid residue 255, a phenylalanine, through amino acid residue 317 of SEQ ID NO: 2, also defined by SEQ ID NO: 6.
  • Zchm-1 may be anchored on the cell membrane via its transmembrane domain and oriented with its carboxyl-terminus outwards.
  • Bovine Chm-I precursor protein is believed to adopt the same configuration on the cell surface, Hiraki et al . BBRC,
  • an alternative dibasic cleavage site may be present at amino acid residues 213-214 of SEQ ID NO: 2.
  • Other than this site there are no obvious alternative processing site in Zchm-1 corresponding to the cleavage site of Chm-I.
  • mature Zchm-1 polypeptide may be a membrane bound protein.
  • growth factors such as tumor necrosis factors, in which family members are either soluble or are membrane dependent on susceptibility to proteolytic processing.
  • POLYNUCLEOTIDES The present invention also provides polynucleotide molecules, including DNA and RNA molecules, that encode the Zchml polypeptides disclosed herein. Those skilled in the art will readily recognize that, in view of the degeneracy of the genetic code, considerable sequence variation is possible among these polynucleotide molecules .
  • Polynucleotides generally a cDNA sequence, of the present invention encode the described polypeptides herein.
  • a cDNA sequence which encodes a polypeptide of the present invention is comprised of a series of codons, each amino acid residue of the polypeptide being encoded by a codon and each codon being comprised of three nucleotides. The amino acid residues are encoded by their respective codons as follows.
  • Alanine (Ala) is encoded by GCA, GCC, GCG or
  • Cysteine (Cys) is encoded by TGC or TGT; Aspartic acid (Asp) is encoded by GAC or GAT Glutamic acid (Glu) is encoded by GAA or GAG Phenylalanine (Phe) is encoded by TTC or TTT
  • Glycine is encoded by GGA, GGC, GGG or GGT;
  • Histidine is encoded by CAC or CAT; Isoleucine (lie) is encoded by ATA, ATC or ATT; Lysine (Lys) is encoded by AAA, or AAG;
  • Leucine (Leu) is encoded by TTA, TTG, CTA, CTC, CTG or CTT;
  • Methionine (Met) is encoded by ATG; Asparagine (Asn) is encoded by AAC or AAT; Proline (Pro) is encoded by CCA, CCC, CCG or
  • Glutamine is encoded by CAA or CAG;
  • Arginine is encoded by AGA, AGG, CGA, CGC, CGG or CGT;
  • Serine (Ser) is encoded by AGC, AGT, TCA, TCC, TCG or TCT;
  • Threonine (Thr) is encoded by ACA, ACC, ACG or
  • Valine (Val) is encoded by GTA, GTC, GTG or GTT; Tryptophan (Trp) is encoded by TGG; and Tyrosine (Tyr) is encoded by TAC or TAT.
  • mRNA messenger RNA
  • T thymine nucleotide
  • U uracil nucleotide
  • preferential codon usage or “preferential codons” is a term of art referring to protein translation codons that are most frequently used in cells of a certain species, thus favoring one or a few representatives of the possible codons encoding each amino acid.
  • the amino acid Threonine (Thr) may be encoded by ACA, ACC, ACG, or ACT, but in mammalian cells ACC is the most commonly used codon; in other species, for example, insect cells, yeast, viruses or bacteria, different Thr codons may be preferential .
  • Preferential codons for a particular species can be introduced into the polynucleotides of the present invention by a variety of methods known in the art. Introduction of preferential codon sequences into recombinant DNA can, for example, enhance production of the protein by making protein translation more efficient within a particular cell type or species. Sequences containing preferential codons can be tested and optimized for expression in various species, and tested for functionality as disclosed herein.
  • the isolated polynucleotides will hybridize to similar sized regions of SEQ ID NO.l, or a sequence complementary thereto, under stringent conditions.
  • stringent conditions are selected to be about 5°C lower than the thermal melting point (T m ) for the specific sequence at a defined ionic strength and pH.
  • T m is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe.
  • Typical stringent conditions are those in which the salt concentration is up to about 0.03 M at pH 7 and the temperature is at least about 60°C.
  • the isolated polynucleotides of the present invention include DNA and RNA.
  • Methods for preparing DNA and RNA are well known in the art.
  • RNA is isolated from a tissue or cell that produces large amounts of Zchml RNA. Such tissues and cells are identified by Northern blotting, Thomas, Proc . Natl . Acad . Sci . USA 77:5201 (1980), and include bone marrow and muscle .
  • Total RNA can be prepared using guanidine HC1 extraction followed by isolation by centrifugation in a CsCl gradient, Chirgwin et a-Z . ,
  • Poly (A) + RNA is prepared from total RNA using the method of Aviv and Leder, Proc.
  • DNA is prepared from poly (A) + RNA using known methods. In the alternative, genomic DNA can be isolated. Polynucleotides encoding Zchml polypeptides are then identified and isolated by, for example, hybridization or PCR.
  • a full-length clone encoding Zchml can be obtained by conventional cloning procedures.
  • Complementary DNA (cDNA) clones are preferred, although for some applications (e . g. , expression in transgenic animals) it may be preferable to use a genomic clone, or to modify a cDNA clone to include at least one genomic intron.
  • Methods for preparing cDNA and genomic clones are well known and within the level of ordinary skill in the art, and include the use of the sequence disclosed herein, or parts thereof, for probing or priming a library.
  • Expression libraries can be probed with antibodies to Zchml, receptor fragments, or other specific binding partners.
  • the polynucleotides of the present invention can also be synthesized using DNA synthesizers.
  • the method of choice is the phosphoramidite method. If chemically synthesized double stranded DNA is required for an application such as the synthesis of a gene or a gene fragment, then each complementary strand is made separately.
  • the production of short genes 60 to 80 bp is technically straightforward and can be accomplished by synthesizing the complementary strands and then annealing them.
  • For the production of longer genes (>300 bp) however, special strategies must be invoked, because the coupling efficiency of each cycle during chemical DNA synthesis is seldom 100%.
  • synthetic genes double-stranded are assembled in modular form from single-stranded fragments that are from 20 to 100 nucleotides in length. See Glick and Pasternak, Molecular Biotechnology, Principles & Applications of
  • the present invention further provides counterpart polypeptides and polynucleotides from other species (orthologs) .
  • species include, but are not limited to mammalian, avian, amphibian, reptile, fish, insect and other vertebrate and invertebrate species .
  • Zchml polypeptides from other mammalian species, including murine, porcine, ovine, bovine, canine, feline, equine, and other primate polypeptides.
  • Orthologs of human Zchml can be cloned using information and compositions provided by the present invention in combination with conventional cloning techniques.
  • a cDNA can be cloned using mRNA obtained from a tissue or cell type that expresses Zchml as disclosed herein. Suitable sources of mRNA can be identified by probing Northern blots with probes designed from the sequences disclosed herein. A library is then prepared from mRNA of a positive tissue or cell line. A Zchml-encoding cDNA can then be isolated by a variety of methods, such as by probing with a complete or partial human cDNA or with one or more sets of degenerate probes based on the disclosed sequences . A cDNA can also be cloned using the polymerase chain reaction, or PCR (Mullis, U.S. Patent No.
  • the cDNA library can be used to transform or transfect host cells, and expression of the cDNA of interest can be detected with an antibody to Zchml polypeptide. Similar techniques can also be applied to the isolation of genomic clones.
  • SEQ ID NO:l represents a single allele of human Zchml and that allelic variation and alternative splicing are expected to occur. Allelic variants of this sequence can be cloned by probing cDNA or genomic libraries from different individuals according to standard procedures. Allelic variants of the DNA sequence shown in SEQ ID NO : 1 , including those containing silent mutations and those in which mutations result in amino acid sequence changes, are within the scope of the present invention, as are proteins which are allelic variants of SEQ ID NO: 2.
  • cDNAs generated from alternatively spliced mRNAs, which retain the properties of the Zchml polypeptide are included within the scope of the present invention, as are polypeptides encoded by such cDNAs and mRNAs .
  • Allelic variants and splice variants of these sequences can be cloned by probing cDNA or genomic libraries from different individuals or tissues according to standard procedures known in the art.
  • the present invention also provides isolated Zchml polypeptides that are substantially homologous to the polypeptides of SEQ ID NO : 2 and their orthologs.
  • substantially homologous is used herein to denote polypeptides having 50%, preferably 60%, more preferably at least 80%, sequence identity to the sequences shown in SEQ ID NO: 2 or their orthologs. Such polypeptides will more preferably be at least 90% identical, and most preferably 95% or more identical to SEQ ID NO: 2 or its orthologs.) Percent sequence identity is determined by conventional methods. See, for example, Altschul et al . , Bull . Math . Bio . 48 : 603-616 (1986) and Henikoff and
  • Sequence identity of polynucleotide molecules is determined by similar methods using a ratio as disclosed above .
  • Variant Zchml polypeptides or substantially homologous Zchml polypeptides are characterized as having one or more amino acid substitutions, deletions or additions. These changes are preferably of a minor nature, that is conservative amino acid substitutions (see Table 2) and other substitutions that do not significantly affect the folding or activity of the polypeptide; small deletions, typically of one to about 30 amino acids; and small amino- or carboxyl-terminal extensions, such as an amino-terminal methionine residue, a small linker peptide of up to about 20-25 residues, or an affinity tag.
  • the present invention thus includes polypeptides of from 20 to 30 amino acid residues that comprise a sequence that is at least 90%, preferably at least 95%, and more preferably 99% or more identical to the corresponding region of SEQ ID NO:4.
  • Polypeptides comprising affinity tags can further comprise a proteolytic cleavage site between the Zchml polypeptide and the affinity tag. Preferred such sites include thrombin cleavage sites and factor Xa cleavage sites.
  • Aromatic phenylalanine tryptophan tyrosine
  • the present invention further provides a variety of other polypeptide fusions [and related multimeric proteins comprising one or more polypeptide fusions] .
  • a Zchml polypeptide can be prepared as a fusion to a dimerizing protein as disclosed in U.S. Patents Nos. 5,155,027 and 5,567,584.
  • Preferred dimerizing proteins in this regard include immunoglobulin constant region domains.
  • Immunoglobulin-Zchml polypeptide fusions can be expressed in genetically engineered cells [to produce a variety of multimeric Zchml analogs] .
  • Auxiliary domains can be fused to Zchml polypeptides to target them to specific cells, tissues, or macromolecules ( e . g.
  • a Zchml polypeptide or protein could be targeted to a predetermined cell type by fusing a Zchml polypeptide to a ligand that specifically binds to a receptor on the surface of the target cell. In this way, polypeptides and proteins can be targeted for therapeutic or diagnostic purposes.
  • a Zchml polypeptide can be fused to two or more moieties, such as an affinity tag for purification and a targeting domain. Polypeptide fusions can also comprise one or more cleavage sites, particularly between domains. See, Tuan et al . , Connective Tissue Research 34 : 1 - 9 (1996).
  • the proteins of the present invention can also comprise non-naturally occurring amino acid residues.
  • Non-naturally occurring amino acids include, without limitation, trans-3-methylproline, 2 , 4-methanoproline, cis-4-hydroxyproline, t-rans-4-hydroxyproline, N- methylglycine, allo-threonine, methylthreonine, hydroxyethylcysteine , hydroxyethylhomocysteine , nitroglutamine, homoglutamine, pipecolic acid, thiazolidine carboxylic acid, dehydroproline, 3- and 4- methylproline, 3 , 3-dimethylproline, tert-leucine, norvaline, 2-azaphenylalanine, 3 -azaphenylalanine, 4- azaphenylalanine, and 4 -fluorophenylalanine .
  • an in vi tro system can be employed wherein
  • E. coli cells are cultured in the absence of a natural amino acid that is to be replaced (e . g. , phenylalanine) and in the presence of the desired non-naturally occurring amino acid(s) (e . g. , 2-azaphenylalanine, 3 -azaphenylalanine, 4- azaphenylalanine, or 4-fluorophenylalanine) .
  • the non-naturally occurring amino acid is incorporated into the protein in place of its natural counterpart. See, Koide et al . , Biochem. 33:7470-7476 (1994).
  • Naturally occurring amino acid residues can be converted to non-naturally occurring species by in vi tro chemical modification.
  • a limited number of non-conservative amino acids, amino acids that are not encoded by the genetic code, non-naturally occurring amino acids, and unnatural amino acids may be substituted for Zchml amino acid residues .
  • Essential amino acids in the polypeptides of the present invention can be identified according to procedures known in the art, such as site-directed mutagenesis or alanine-scanning mutagenesis, Cunningham and Wells, Science 244 : 1081-1085 (1989); Bass et al . ,
  • Sites of ligand-receptor interaction can also be determined by physical analysis of structure, as determined by such techniques as nuclear magnetic resonance, crystallography, electron diffraction or photoaffinity labeling, in conjunction with mutation of putative contact site amino acids. See, for example, de Vos et al . , Science 255:306-312 (1992); Smith et al . , J.
  • Variants of the disclosed Zchml DNA and polypeptide sequences can be generated through DNA shuffling as disclosed by Stemmer, Na ture 370:389-391, (1994), Stemmer, Proc . Natl . Acad. Sci . USA 91:10747-10751
  • variant DNAs are generated by in vi tro homologous recombination by random fragmentation of a parent DNA followed by reassembly using PCR, resulting in randomly introduced point mutations.
  • This technique can be modified by using a family of parent DNAs, such as allelic variants or DNAs from different species, to introduce additional variability into the process. Selection or screening for the desired activity, followed by additional iterations of mutagenesis and assay provides for rapid "evolution" of sequences by selecting for desirable mutations while simultaneously selecting against detrimental changes.
  • Mutagenesis methods as disclosed herein can be combined with high-throughput , automated screening methods to detect activity of cloned, mutagenized polypeptides in host cells.
  • Mutagenized DNA molecules that encode active polypeptides can be recovered from the host cells and rapidly sequenced using modern equipment. These methods allow the rapid determination of the importance of individual amino acid residues in a polypeptide of interest, and can be applied to polypeptides of unknown structure .
  • the Zchml polypeptides of the present invention can be produced in genetically engineered host cells according to conventional techniques.
  • Suitable host cells are those cell types that can be transformed or transfected with exogenous DNA and grown in culture, and include bacteria, fungal cells, and cultured higher eukaryotic cells. Eukaryotic cells, particularly cultured cells of multicellular organisms, are preferred. Techniques for manipulating cloned DNA molecules and introducing exogenous DNA into a variety of host cells are disclosed by Sambrook et al . , Molecular Cloning: A Laboratory
  • a DNA sequence encoding a Zchml polypeptide is operably linked to other genetic elements required for its expression, generally including a transcription promoter and terminator, within an expression vector.
  • the vector will also commonly contain one or more selectable markers and one or more origins of replication, although those skilled in the art will recognize that within certain systems selectable markers may be provided on separate vectors, and replication of the exogenous DNA may be provided by integration into the host cell genome. Selection of promoters, terminators, selectable markers, vectors and other elements is a matter of routine design within the level of ordinary skill in the ar . Many such elements are described in the literature and are available through commercial suppliers.
  • a secretory signal sequence (also known as a leader sequence, prepro sequence or pre sequence) is provided in the expression vector.
  • the secretory signal sequence may be that of Zchml, or may be derived from another secreted protein (e. g. , t-PA) or synthesized de novo .
  • the secretory signal sequence is operably linked to the Zchml DNA sequence, i.e., the two sequences are joined in the correct reading frame and positioned to direct the newly synthesized polypeptide into the secretory pathway of the host cell .
  • Secretory signal sequences are commonly positioned 5 ' to the DNA sequence encoding the polypeptide of interest, although certain secretory signal sequences may be positioned elsewhere in the DNA sequence of interest (see, e . g. ,
  • the secretory signal sequence contained in the polypeptides of the present invention is used to direct other polypeptides into the secretory pathway.
  • the present invention provides for such fusion polypeptides.
  • the secretory signal sequence contained in the fusion polypeptides of the present invention is preferably fused amino-terminally to an additional peptide to direct the additional peptide into the secretory pathway.
  • Such constructs have numerous applications known in the art.
  • these novel secretory signal sequence fusion constructs can direct the secretion of an active component of a normally non-secreted protein, such as a receptor. Such fusions may be used in vivo or in vi tro to direct peptides through the secretory pathway.
  • Cultured mammalian cells are suitable hosts within the present invention.
  • Methods for introducing exogenous DNA into mammalian host cells include calcium phosphate-mediated transfection, Wigler et al . , Cell
  • Suitable cultured mammalian cells include the COS-1 (ATCC No. CRL 1650), COS-7 (ATCC No. CRL 1651), BHK (ATCC No. CRL 1632), BHK 570 (ATCC No. CRL 10314), 293 (ATCC No. CRL 1573; Graham et al . , J. Gen . Virol . 36: 59 (1977) and
  • Chinese hamster ovary e . g. CHO-K1; ATCC No. CCL 61 cell lines. Additional suitable cell lines are known in the art and available from public depositories such as the American Type Culture Collection, Rockville, Maryland. In general, strong transcription promoters are preferred, such as promoters from SV-40 or cytomegalovirus. See, e . g. , U.S. Patent No. 4,956,288. Other suitable promoters include those from metallothionein genes (U.S. Patent Nos. 4,579,821 and 4,601,978) and the adenovirus major late promoter.
  • Drug selection is generally used to select for cultured mammalian cells into which foreign DNA has been inserted. Such cells are commonly referred to as “transfectants” . Cells that have been cultured in the presence of the selective agent and are able to pass the gene of interest to their progeny are referred to as “stable transfectants . " A preferred selectable marker is a gene encoding resistance to the antibiotic neomycin. Selection is carried out in the presence of a neomycin- type drug, such as G-418 or the like.
  • Selection systems can also be used to increase the expression level of the gene of interest, a process referred to as "amplification.” Amplification is carried out by culturing transfectants in the presence of a low level of the selective agent and then increasing the amount of selective agent to select for cells that produce high levels of the products of the introduced genes.
  • a preferred amplifiable selectable marker is dihydrofolate reductase, which confers resistance to methotrexate .
  • Other drug resistance genes e . g. hygromycin resistance, multi-drug resistance, puromycin acetyltransferase
  • drug resistance genes e . g. hygromycin resistance, multi-drug resistance, puromycin acetyltransferase
  • Alternative markers that introduce an altered phenotype such as green fluorescent protein, or cell surface proteins such as CD4 , CD8 , Class I MHC, placental alkaline phosphatase may be used to sort transfected cells from untransfected cells by such means as FACS sorting or magnetic bead separation technology.
  • Agrobacterium rhizogenes as a vector for expressing genes in plant cells has been reviewed by Sinkar et al . , J. Biosci . (Bangalore) 11 : 47 (1987).
  • Insect cells can be infected with recombinant baculovirus, commonly derived from Autographa californica nuclear polyhedrosis virus (AcNPV) .
  • DNA encoding the Zchml polypeptide is inserted into the baculoviral genome in place of the AcNPV polyhedrin gene coding sequence by one of two methods. The first is the traditional method of homologous DNA recombination between wild-type AcNPV and a transfer vector containing the Zchml flanked by AcNPV sequences.
  • Suitable insect cells e . g.
  • SF9 cells are infected with wild-type AcNPV and transfected with a transfer vector comprising a Zchml polynucleotide operably linked to an AcNPV polyhedrin gene promoter, terminator, and flanking sequences.
  • a transfer vector comprising a Zchml polynucleotide operably linked to an AcNPV polyhedrin gene promoter, terminator, and flanking sequences.
  • the second method of making recombinant baculovirus utilizes a transposon-based system described by Luckow, V.A, et al . , J Virol 67 : 4566 (1993).
  • This system is sold in the Bac-to-Bac kit (Life Technologies, Rockville, MD) .
  • This system utilizes a transfer vector, pFastBaclTM (Life Technologies) containing a Tn7 transposon to move the DNA encoding the Zchml polypeptide into a baculovirus genome maintained in E. coli as a large plasmid called a "bacmid.
  • the pFastBaclTM transfer vector utilizes the AcNPV polyhedrin promoter to drive the expression of the gene of interest, in this case Zchml.
  • pFastBaclTM can be modified to a considerable degree .
  • the polyhedrin promoter can be removed and substituted with the baculovirus basic protein promoter (also known as Pcor, p6.9 or MP promoter) which is expressed earlier in the baculovirus infection, and has been shown to be advantageous for expressing secreted proteins. See, Hill-Perkins, M.S. and Possee, R.D., J " Gen
  • transfer vector constructs a short or long version of the basic protein promoter can be used.
  • transfer vectors can be constructed which replace the native Zchml secretory signal sequences with secretory signal sequences derived from insect proteins.
  • a secretory signal sequence from Ecdysteroid Glucosyltransferase (EGT) , honey bee Melittin (Invitrogen, Carlsbad, CA) , or baculovirus gp67 (PharMingen, San Diego, CA) can be used in constructs to replace the native Zchml secretory signal sequence.
  • transfer vectors can include an in-frame fusion with DNA encoding an epitope tag at the C- or N-terminus of the expressed Zchml polypeptide, for example, a Glu-Glu epitope tag, Grussenmeyer, T. et al . , Proc Natl Acad Sci .
  • a transfer vector containing Zchml is transformed into E. coli , and screened for bacmids which contain an interrupted lacZ gene indicative of recombinant baculovirus .
  • the bacmid DNA containing the recombinant baculovirus genome is isolated, using common techniques, and used to transfect Spodoptera frugiperda cells, e . g.
  • Recombinant virus that expresses Zchml is subsequently produced.
  • Recombinant viral stocks are made by methods commonly used the art .
  • the recombinant virus is used to infect host cells, typically a cell line derived from the fall army worm, Spodoptera frugiperda . See, in general, Glick and
  • Another suitable cell line is the High FiveOTM cell line (Invitrogen) derived from Trichoplusia ni
  • Suitable media are Sf900 IITM (Life Technologies) or ESF 921TM (Expression Systems) for the Sf9 cells; and Ex- cellO405TM (JRH Biosciences, Lenexa, KS) or Express FiveOTM (Life Technologies) for the T. ni cells.
  • the cells are grown up from an inoculation density of approximately 2-5 x 10 5 cells to a density of 1-2 x 10 6 cells at which time a recombinant viral stock is added at a multiplicity of infection (MOD of 0.1 to 10, more typically near 3.
  • MOD multiplicity of infection
  • the recombinant virus-infected cells typically produce the recombinant Zchml polypeptide at 12-72 hours post- infection and secrete it with varying efficiency into the medium.
  • the culture is usually harvested 48 hours post- infection. Centrifugation is used to separate the cells from the medium (supernatant) .
  • the supernatant containing the Zchml polypeptide is filtered through micropore filters, usually 0.45 ⁇ m pore size. Procedures used are generally described in available laboratory manuals (King, L. A. and Possee, R.D., ibid. ; O'Reilly, D.R. et al . , ibid. ; Richardson, C. D., ibid. ) . Subsequent purification of the Zchml polypeptide from the supernatant can be achieved using methods described herein.
  • Fungal cells including yeast cells, can also be used within the present invention.
  • Yeast species of particular interest in this regard include Saccharomyces cerevisiae, Pichia pastoris, and Pichia methanolica .
  • Methods for transforming S. cerevisiae cells with exogenous DNA and producing recombinant polypeptides therefrom are disclosed by, for example, Kawasaki, U.S. Patent No. 4,599,311; Kawasaki et al . , U.S. Patent No.
  • Transformed cells are selected by phenotype determined by the selectable marker, commonly drug resistance or the ability to grow in the absence of a particular nutrient (e . g. , leucine) .
  • a preferred vector system for use in Saccharomyces cerevisiae is the POT1 vector system disclosed by Kawasaki et al . (U.S. Patent
  • Suitable promoters and terminators for use in yeast include those from glycolytic enzyme genes (see, e . g. , Kawasaki, U.S.
  • Transformation systems for other yeasts including Hansenula polymorpha, Schizosaccharomyces pombe,
  • Kluyveromyces lactis, Kluyveromyces fragilis, Ustilago maydis, Pichia pastoris , Pichia methanolica, Pichia guillermondii and Candida mal tosa are known in the art. See, for example, Gleeson et al . , J. Gen . Microbiol . 132 : 3459 (1986) and Cregg, U.S. Patent No. 4,882,279. Aspergillus cells may be utilized according to the methods of McKnight et al., U.S. Patent No. 4,935,349. Methods for transforming Acremonium chrysogenum are disclosed by Sumino et a-Z., U.S. Patent No. 5,162,228. Methods for transforming Neurospora are disclosed by Lambowitz, U.S. Patent No. 4,486,533.
  • Pichia methanolica as host for the production of recombinant proteins is disclosed in WIPO Publications WO 97/17450, WO 97/17451, WO 98/02536, and WO 98/02565.
  • DNA molecules for use in transforming P. methanolica will commonly be prepared as double-stranded, circular plasmids, which are preferably linearized prior to transformation.
  • the promoter and terminator in the plasmid be that of a P. methanolica gene, such as a P. methanolica alcohol utilization gene
  • a preferred selectable marker for use in Pichia methanolica is a P. methanolica ADE2 gene, which encodes phosphoribosyl-5-aminoimidazole carboxylase (AIRC; EC 4.1.1.21), which allows ade2 host cells to grow in the absence of adenine .
  • Electroporation is used to facilitate the introduction of a plasmid containing DNA encoding a polypeptide of interest into P. methanolica cells. It is preferred to transform P. methanolica cells by electroporation using an exponentially decaying, pulsed electric field having a field strength of from 2.5 to 4.5 kV/cm, preferably about 3.75 kV/cm, and a time constant (t) of from 1 to 40 milliseconds, most preferably about 20 milliseconds.
  • Prokaryotic host cells including strains of the bacteria Escherichia coli , Bacillus and other genera are also useful host cells within the present invention. Techniques for transforming these hosts and expressing foreign DNA sequences cloned therein are well known in the art, see, e . g. , Sambrook et al . , ibid. ) .
  • the polypeptide When expressing a Zchml polypeptide in bacteria such as E. coli , the polypeptide may be retained in the cytoplasm, typically as insoluble granules, or may be directed to the periplasmic space by a bacterial secretion sequence.
  • the cells are lysed, and the granules are recovered and denatured using, for example, guanidine isothiocyanate or urea.
  • the denatured polypeptide can then be refolded and dimerized by diluting the denaturant, such as by dialysis against a solution of urea and a combination of reduced and oxidized glutathione, followed by dialysis against a buffered saline solution.
  • the polypeptide can be recovered from the periplasmic space in a soluble and functional form by disrupting the cells (by, for example, sonication or osmotic shock) to release the contents of the periplasmic space and recovering the protein, thereby obviating the need for denaturation and refolding.
  • Transformed or transfected host cells are cultured according to conventional procedures in a culture medium containing nutrients and other components required for the growth of the chosen host cells.
  • suitable media including defined media and complex media, are known in the art and generally include a carbon source, a nitrogen source, essential amino acids, vitamins and minerals . Media may also contain such components as growth factors or serum, as required.
  • the growth medium will generally select for cells containing the exogenously added DNA by, for example, drug selection or deficiency in an essential nutrient which is complemented by the selectable marker carried on the expression vector or co- transfected into the host cell.
  • P. methanolica cells are cultured in a medium comprising adequate sources of carbon, nitrogen and trace nutrients at a temperature of about 25°C to 35°C. Liquid cultures are provided with sufficient aeration by conventional means, such as shaking of small flasks or sparging of fermentors .
  • a preferred culture medium for P. methanolica is YEPD (2% D-glucose,
  • polypeptides of the present invention it is preferred to purify the polypeptides of the present invention to >80% purity, more preferably to >90% purity, even more preferably >95% purity, and particularly preferred is a pharmaceutically pure state, that is greater than 99.9% pure with respect to contaminating macromolecules, particularly other proteins and nucleic acids, and free of infectious and pyrogenic agents.
  • a purified polypeptide is substantially free of other polypeptides, particularly other polypeptides of animal origin.
  • Expressed recombinant Zchml polypeptides can be purified using fractionation and/or conventional purification methods and media.
  • Ammonium sulfate precipitation and acid or chaotrope extraction may be used for fractionation of samples .
  • Exemplary purification steps may include hydroxyapatite, size exclusion, FPLC and reverse-phase high performance liquid chromatography.
  • Suitable chromatographic media include derivatized dextrans, agarose, cellulose, polyacrylamide, specialty silicas, and the like. PEI, DEAE, QAE and Q derivatives are preferred.
  • Exemplary chromatographic media include those media derivatized with phenyl, butyl, or octyl groups, such as
  • Phenyl-Sepharose FF (Pharmacia) , Toyopearl butyl 650 (Toso Haas, Montgomeryville, PA) , Octyl -Sepharose (Pharmacia) and the like; or polyacrylic resins, such as Amberchrom CG 71 (Toso Haas) and the like.
  • Suitable solid supports include glass beads, silica-based resins, cellulosic resins, agarose beads, cross-linked agarose beads, polystyrene beads, cross-linked polyacrylamide resins and the like that are insoluble under the conditions in which they are to be used.
  • These supports may be modified with reactive groups that allow attachment of proteins by amino groups, carboxyl groups, sulfhydryl groups, hydroxyl groups and/or carbohydrate moieties.
  • Examples of coupling chemistries include cyanogen bromide activation, N- hydroxysuccinimide activation, epoxide activation, sulfhydryl activation, hydrazide activation, and carboxyl and amino derivatives for carbodiimide coupling chemistries.
  • These and other solid media are well known and widely used in the art, and are available from commercial suppliers.
  • Methods for binding receptor polypeptides to support media are well known in the art. Selection of a particular method is a matter of routine design and is determined in part by the properties of the chosen support. See, for example, Affini ty
  • polypeptides of the present invention can be isolated by exploitation of their properties.
  • immobilized metal ion adsorption (IMAC) chromatography can be used to purify histidine-rich proteins, including those comprising polyhistidine tags. Briefly, a gel is first charged with divalent metal ions to form a chelate, Sulkowski, Trends in Biochem. 3 : 1
  • Histidine-rich proteins will be adsorbed to this matrix with differing affinities, depending upon the metal ion used, and will be eluted by competitive elution, lowering the pH, or use of strong chelating agents.
  • Other methods of purification include purification of glycosylated proteins by lectin affinity chromatography and ion exchange chromatography. Methods in Enzymol . , Vol.
  • a fusion of the polypeptide of interest and an affinity tag may be constructed to facilitate purification.
  • an affinity tag e.g., maltose-binding protein, an immunoglobulin domain
  • polypeptide fusions, or hybrid Zchml proteins are constructed using regions or domains of the inventive Zchml, Sambrook et al . , ibid. , Altschul et al . , ibid. , Picard, Cur. Opin . Biology, 5:511 (1994). These methods allow the determination of the biological importance of larger domains or regions in a polypeptide of interest.
  • Such hybrids may alter reaction kinetics, binding, constrict or expand the substrate specificity, or alter tissue and cellular localization of a polypeptide, and can be applied to polypeptides of unknown structure.
  • Fusion proteins can be prepared by methods known to those skilled in the art by preparing each component of the fusion protein and chemically conjugating them.
  • a polynucleotide encoding both components of the fusion protein in the proper reading frame can be generated using known techniques and expressed by the methods described herein.
  • part or all of a domain (s) conferring a biological function may be swapped between Zchml of the present invention with the functionally equivalent domain (s) from another family member.
  • domains include, but are not limited to, the secretory signal sequence, conserved, and significant domains or regions in this family.
  • Such fusion proteins would be expected to have a biological functional profile that is the same or similar to polypeptides of the present invention or other known family proteins, depending on the fusion constructed. Moreover, such fusion proteins may exhibit other properties as disclosed herein.
  • Zchml polypeptides or fragments thereof may also be prepared through chemical synthesis.
  • Zchml polypeptides may be monomers or multimers; glycosylated or non- glycosylated; pegylated or non-pegylated; and may or may not include an initial methionine amino acid residue.
  • Polypeptides especially polypeptides of the present invention can also be synthesized by exclusive solid phase synthesis, partial solid phase methods, fragment condensation or classical solution synthesis.
  • the polypeptides are preferably prepared by solid phase peptide synthesis, for example as described by Merrifield, J " . Am . Chem . Soc . 85 : 2149 (1963) .
  • Zchml can be measured in vi tro using cultured cells or in vivo by administering molecules of the claimed invention to the appropriate animal model.
  • Zchml transfected (or co-transfected) expression host cells may be embedded in an alginate environment and injected (implanted) into recipient animals.
  • Alginate-poly-L-lysine microencapsulation, permselective membrane encapsulation and diffusion chambers have been described as a means to entrap transfected mammalian cells or primary mammalian cells.
  • non-immunogenic "encapsulations” or microenvironments permit the transfer of nutrients into the microenvironment, and also permit the diffusion of proteins and other macromolecules secreted or released by the captured cells across the environmental barrier to the recipient animal. Most importantly, the capsules or microenvironments mask and shield the foreign, embedded cells from the recipient animal's immune response. Such microenvironments can extend the life of the injected cells from a few hours or days (naked cells) to several weeks (embedded cells) .
  • viruses for this purpose include adenovirus, herpesvirus, vaccinia virus and adeno- associated virus (AAV) .
  • Adenovirus a double-stranded DNA virus, is currently the best studied gene transfer vector for delivery of heterologous nucleic acid (for a review, see T.C. Becker et al . , Meth . Cell Biol . 43 : 161 (1994); and J.T. Douglas and D.T. Curiel, Science & Medicine 4 : 44
  • adenovirus can (i) accommodate relatively large DNA inserts; (ii) be grown to high-titer; (iii) infect a broad range of mammalian cell types; and (iv) be used with a large number of available vectors containing different promoters. Also, because adenoviruses are stable in the bloodstream, they can be administered by intravenous injection.
  • adenovirus By deleting portions of the adenovirus genome, larger inserts (up to 7 kb) of heterologous DNA can be accommodated. These inserts can be incorporated into the viral DNA by direct ligation or by homologous recombination with a co-transfected plasmid.
  • the essential El gene has been deleted from the viral vector, and the virus will not replicate unless the El gene is provided by the host cell (the human 293 cell line is exemplary) .
  • the host cell the human 293 cell line is exemplary
  • adenovirus When intravenously administered to intact animals, adenovirus primarily targets the liver. If the adenoviral delivery system has an El gene deletion, the virus cannot replicate in the host cells.
  • the host's tissue e.g., liver
  • the host's tissue will express and process (and, if a secretory signal sequence is present, secrete) the heterologous protein.
  • Secreted proteins will enter the circulation in the highly vascularized liver, and effects on the infected animal can be determined.
  • the adenovirus system can also be used for protein production in vi tro .
  • the cells By culturing adenovirus- infected non-293 cells under conditions where the cells are not rapidly dividing, the cells can produce proteins for extended periods of time. For instance, BHK cells are grown to confluence in cell factories, then exposed to the adenoviral vector encoding the secreted protein of interest. The cells are then grown under serum-free conditions, which allows infected cells to survive for several weeks without significant cell division.
  • adenovirus vector infected 293S cells can be grown in suspension culture at relatively high cell density to produce significant amounts of protein (see Gamier et al . , Cytotechnol . 15 : 145 (1994). With either protocol, an expressed, secreted heterologous protein can be repeatedly isolated from the cell culture supernatant. Within the infected 293S cell production protocol, non- secreted proteins may also be effectively obtained.
  • agonists including the natural ligand/ substrate/ cofactor/ etc.
  • antagonists have enormous potential in both in vi tro and in vivo applications.
  • Zchml and agonist compounds are useful as components of defined cell culture media, and may be used alone or in combination with other cytokines and hormones to replace serum that is commonly used in cell culture.
  • Antagonists are also useful as research reagents for characterizing sites of ligand-receptor interaction. Also as a treatment for prostate cancer.
  • Inhibitors of Zchml activity include anti-Zchml antibodies and soluble Zchml receptors, as well as other peptidic and non-peptidic agents (including ribozymes) .
  • Zchml can also be used to identify inhibitors (antagonists) of its activity. Test compounds are added to the assays disclosed herein to identify compounds that inhibit the activity of Zchml.
  • samples can be tested for inhibition of Zchml activity within a variety of assays designed to measure receptor binding or the stimulation/inhibition of Zchml-dependent cellular responses.
  • Zchml-responsive cell lines can be transfected with a reporter gene construct that is responsive to a Zchml-stimulated cellular pathway.
  • Reporter gene constructs of this type are known in the art, and will generally comprise a Zchml-DNA response element operably linked to a gene encoding a protein which can be assayed, such as luciferase.
  • DNA response elements can include, but are not limited to, cyclic AMP response elements (CRE) , hormone response elements (HRE) insulin response element (IRE), Nasrin et al . , Proc. Na tl . Acad.
  • CRE cyclic AMP response elements
  • HRE hormone response elements
  • IRE insulin response element
  • Receptors used within binding assays may be cellular receptors or isolated, immobilized receptors.
  • a Zchml polypeptide can be expressed as a fusion with an immunoglobulin heavy chain constant region, typically an F c fragment, which contains two constant region domains and lacks the variable region.
  • an immunoglobulin heavy chain constant region typically an F c fragment
  • Methods for preparing such fusions are disclosed in U.S. Patents Nos. 5,155,027 and 5,567,584.
  • Such fusions are typically secreted as multimeric molecules wherein the Fc portions are disulfide bonded to each other and two non-Ig polypeptides are arrayed in closed proximity to each other. Fusions of this type can be used to affinity purify the ligand.
  • the chimeras are bound to a support via the F c region and used in an ELISA format .
  • a Zchml ligand-binding polypeptide can also be used for purification of ligand.
  • the polypeptide is immobilized on a solid support, such as beads of agarose, cross-linked agarose, glass, cellulosic resins, silica- based resins, polystyrene, cross-linked polyacrylamide, or like materials that are stable under the conditions of use.
  • a solid support such as beads of agarose, cross-linked agarose, glass, cellulosic resins, silica- based resins, polystyrene, cross-linked polyacrylamide, or like materials that are stable under the conditions of use.
  • Methods for linking polypeptides to solid supports are known in the art, and include amine chemistry, cyanogen bromide activation, N-hydroxysuccinimide activation, epoxide activation, sulfhydryl activation, and hydrazide activation.
  • the resulting medium will generally be configured in the form of a column, and fluids containing ligand are passed through the column one or more times to allow ligand to bind to the receptor polypeptide.
  • the ligand is then eluted using changes in salt concentration, chaotropic agents (guanidine HCl) , or pH to disrupt ligand-receptor binding.
  • An assay system that uses a ligand-binding receptor (or an antibody, one member of a complement/ anti -complement pair) or a binding fragment thereof, and a commercially available biosensor instrument (BIAcore, Pharmacia Biosensor, Piscataway, NJ) may be advantageously employed.
  • a ligand-binding receptor or an antibody, one member of a complement/ anti -complement pair
  • a commercially available biosensor instrument (BIAcore, Pharmacia Biosensor, Piscataway, NJ)
  • Such receptor, antibody, member of a complement/anti-complement pair or fragment is immobilized onto the surface of a receptor chip. Use of this instrument is disclosed by Karlsson, J. Immunol . Methods
  • a receptor, antibody, member or fragment is covalently attached, using amine or sulfhydryl chemistry, to dextran fibers that are attached to gold film within the flow cell.
  • a test sample is passed through the cell. If a ligand, epitope, or opposite member of the complement/anti-complement pair is present in the sample, it will bind to the immobilized receptor, antibody or member, respectively, causing a change in the refractive index of the medium, which is detected as a change in surface plasmon resonance of the gold film.
  • This system allows the determination of on- and off-rates, from which binding affinity can be calculated, and assessment of stoichiometry of binding.
  • Ligand-binding receptor polypeptides can also be used within other assay systems known in the art . Such systems include Scatchard analysis for determination of binding affinity, Scatchard, Ann. NY Acad. Sci . 51 : 660 (1949) and calorimetric assays,
  • Zchml polypeptides can also be used to prepare antibodies that specifically bind to Zchml epitopes, peptides or polypeptides.
  • the Zchml polypeptide or a fragment thereof serves as an antigen (immunogen) to inoculate an animal and elicit an immune response.
  • Suitable antigens would be the Zchml polypeptides encoded by SEQ ID NOs:2-24.
  • Antibodies generated from this immune response can be isolated and purified as described herein. Methods for preparing and isolating polyclonal and monoclonal antibodies are well known in the art. See, for example, Current Protocols in Immunology, Cooligan, et al .
  • polyclonal antibodies can be generated from inoculating a variety of warm-blooded animals such as horses, cows, goats, sheep, dogs, chickens, rabbits, mice, and rats with a Zchml polypeptide or a fragment thereof.
  • the immunogenicity of a Zchml polypeptide may be increased through the use of an adjuvant, such as alum (aluminum hydroxide) or Freund's complete or incomplete adjuvant.
  • Polypeptides useful for immunization also include fusion polypeptides, such as fusions of Zchml or a portion thereof with an immunoglobulin polypeptide or with maltose binding protein.
  • the polypeptide immunogen may be a full- length molecule or a portion thereof. If the polypeptide portion is "hapten-like" , such portion may be advantageously joined or linked to a macromolecular carrier (such as keyhole limpet hemocyanin (KLH) , bovine serum albumin (BSA) or tetanus toxoid) for immunization.
  • a macromolecular carrier such as keyhole limpet hemocyanin (KLH) , bovine serum albumin (BSA) or tetanus toxoid
  • antibodies includes polyclonal antibodies, affinity-purified polyclonal antibodies, monoclonal antibodies, and antigen-binding fragments, such as F(ab')2 and Fab proteolytic fragments.
  • Non-human antibodies may be humanized by grafting non-human CDRs onto human framework and constant regions, or by incorporating the entire non-human variable domains (optionally "cloaking" them with a human-like surface by replacement of exposed residues, wherein the result is a "veneered” antibody) .
  • humanized antibodies may retain non-human residues within the human variable region framework domains to enhance proper binding characteristics.
  • Alternative techniques for generating or selecting antibodies useful herein include in vi tro exposure of lymphocytes to Zchml protein or peptide, and selection of antibody display libraries in phage or similar vectors (for instance, through use of immobilized or labeled Zchml protein or peptide) .
  • Genes encoding polypeptides having potential Zchml polypeptide binding domains can be obtained by screening random peptide libraries displayed on phage (phage display) or on bacteria, such as E. coli .
  • Nucleotide sequences encoding the polypeptides can be obtained in a number of ways, such as through random mutagenesis and random polynucleotide synthesis.
  • random peptide display libraries can be used to screen for peptides which interact with a known target which can be a protein or polypeptide, such as a ligand or receptor, a biological or synthetic macromolecule, or organic or inorganic substances.
  • a known target which can be a protein or polypeptide, such as a ligand or receptor, a biological or synthetic macromolecule, or organic or inorganic substances.
  • Techniques for creating and screening such random peptide display libraries are known in the art (Ladner et al . , US
  • Random peptide display libraries can be screened using the Zchml sequences disclosed herein to identify proteins which bind to Zchml.
  • binding proteins which interact with Zchml polypeptides can be used for tagging cells; for isolating homolog polypeptides by affinity purification; they can be directly or indirectly conjugated to drugs, toxins, radionuclides and the like. These binding proteins can also be used in analytical methods such as for screening expression libraries and neutralizing activity. The binding proteins can also be used for diagnostic assays for determining circulating levels of polypeptides; for detecting or quantitating soluble polypeptides as marker of underlying pathology or disease. These binding proteins can also act as Zchml "antagonists" to block Zchml binding and signal transduction in vi tro and in vivo .
  • Antibodies are determined to be specifically binding if: (1) they exhibit a threshold level of binding activity, and/or 2) they do not significantly cross-react with related polypeptide molecules.
  • antibodies herein specifically bind if they bind to a Zchml polypeptide, peptide or epitope with a binding affinity
  • the binding affinity of an antibody can be readily determined by one of ordinary skill in the art, for example, by Scatchard analysis.
  • Second, antibodies are determined to specifically bind if they do not significantly cross-react with related polypeptides. Antibodies do not significantly cross-react with related polypeptide molecules, for example, if they detect Zchml but not known related polypeptides using a standard
  • antibodies may be "screened against" known related polypeptides to isolate a population that specifically binds to the inventive polypeptides. For example, antibodies raised to Zchml are adsorbed to related polypeptides adhered to insoluble matrix; antibodies specific to Zchml will flow through the matrix under the proper buffer conditions. Such screening allows isolation of polyclonal and monoclonal antibodies non- crossreactive to closely related polypeptides, Antibodies :
  • Representative examples of such assays include: concurrent immunoelectrophoresis, radioimmunoassay, radioimmuno-precipitation, enzyme-linked immunosorbent assay (ELISA) , dot blot or Western blot assay, inhibition or competition assay, and sandwich assay.
  • ELISA enzyme-linked immunosorbent assay
  • dot blot or Western blot assay inhibition or competition assay
  • sandwich assay antibodies can be screened for binding to wild-type versus mutant Zchml protein or polypeptide.
  • Antibodies to Zchml may be used for tagging cells that express Zchml; for isolating Zchml by affinity purification; for diagnostic assays for determining circulating levels of Zchml polypeptides; for detecting or quantitating soluble Zchml as marker of underlying pathology or disease; in analytical methods employing FACS; for screening expression libraries; for generating anti-idiotypic antibodies; and as neutralizing antibodies or as antagonists to block Zchml in vi tro and in vivo .
  • Suitable direct tags or labels include radionuclides, enzymes, substrates, cofactors, inhibitors, fluorescent markers, chemiluminescent markers, magnetic particles and the like; indirect tags or labels may feature use of biotin-avidin or other complement/anti-complement pairs as intermediates.
  • Antibodies herein may also be directly or indirectly conjugated to drugs, toxins, radionuclides and the like, and these conjugates used for in vivo diagnostic or therapeutic applications.
  • antibodies to Zchml or fragments thereof may be used in vi tro to detect denatured Zchml or fragments thereof in assays, for example, Western Blots or other assays known in the art.
  • Antibodies or polypeptides herein can also be directly or indirectly conjugated to drugs, toxins, radionuclides and the like, and these conjugates used for in vivo diagnostic or therapeutic applications.
  • polypeptides or antibodies of the present invention can be used to identify or treat tissues or organs that express a corresponding anti-complementary molecule (receptor or antigen, respectively, for instance) .
  • Zchml polypeptides or anti- Zchml antibodies, or bioactive fragments or portions thereof can be coupled to detectable or cytotoxic molecules and delivered to a mammal having cells, tissues or organs that express the anti-complementary molecule.
  • Suitable detectable molecules may be directly or indirectly attached to the polypeptide or antibody, and include radionuclides, enzymes, substrates, cofactors, inhibitors, fluorescent markers, chemiluminescent markers, magnetic particles and the like.
  • Suitable cytotoxic molecules may be directly or indirectly attached to the polypeptide or antibody, and include bacterial or plant toxins (for instance, diphtheria toxin, Pseudomonas exotoxin, ricin, abrin and the like) , as well as therapeutic radionuclides, such as iodine-131, rhenium-188 or yttrium- 90 (either directly attached to the polypeptide or antibody, or indirectly attached through means of a chelating moiety, for instance) .
  • Polypeptides or antibodies may also be conjugated to cytotoxic drugs, such as adriamycin.
  • cytotoxic drugs such as adriamycin.
  • the detectable or cytotoxic molecule can be conjugated with a member of a complementary/ anticomplementary pair, where the other member is bound to the polypeptide or antibody portion.
  • biotin/streptavidin is an exemplary complementary/ anticomplementary pair.
  • polypeptide-toxin fusion proteins or antibody-toxin fusion proteins can be used for targeted cell or tissue inhibition or ablation (for instance, to treat cancer cells or tissues) .
  • a fusion protein including only the targeting domain may be suitable for directing a detectable molecule, a cytotoxic molecule or a complementary molecule to a cell or tissue type of interest .
  • the domain only fusion protein includes a complementary molecule
  • the anti- complementary molecule can be conjugated to a detectable or cytotoxic molecule.
  • Such domain-complementary molecule fusion proteins thus represent a generic targeting vehicle for cell/tissue-specific delivery of generic anti- complementary-detectable/ cytotoxic molecule conjugates.
  • Zchml-cytokine fusion proteins or antibody-cytokine fusion proteins can be used for enhancing in vivo killing of target tissues (for example, blood and bone marrow cancers) , if the Zchml polypeptide or anti-Zchml antibody targets the hyperproliterative blood or bone marrow cell.
  • target tissues for example, blood and bone marrow cancers
  • Zchml polypeptide or anti-Zchml antibody targets the hyperproliterative blood or bone marrow cell.
  • Suitable Zchml polypeptides or anti-Zchml antibodies target an undesirable cell or tissue (i.e., a tumor or a leukemia), and the fused cytokine mediated improved target cell lysis by effector cells.
  • Suitable cytokines for this purpose include interleukin 2 and granulocyte-macrophage colony- stimulating factor (GM-CSF) , for instance.
  • GM-CSF granulocyte-macrophage colony- stimulating factor
  • the Zchml polypeptide or anti-Zchml antibody targets vascular cells or tissues
  • such polypeptide or antibody may be conjugated with a radionuclide, and particularly with a beta-emitting radionuclide, to reduce restenosis.
  • a radionuclide and particularly with a beta-emitting radionuclide
  • Such therapeutic approach poses less danger to clinicians who administer the radioactive therapy. For instance, iridium-192 impregnated ribbons placed into stented vessels of patients until the required radiation dose was delivered showed decreased tissue growth in the vessel and greater luminal diameter than the control group, which received placebo ribbons. Further, revascularisation and stent thrombosis were significantly lower in the treatment group. Similar results are predicted with targeting of a bioactive conjugate containing a radionuclide, as described herein.
  • bioactive polypeptide or antibody conjugates described herein can be delivered intravenously, intraarterially or intraductally, or may be introduced locally at the intended site of action.
  • the polypeptides of the present invention can be used as a growth or differentiation regulator for cells, especially those of the mesenchymal, myogenic, chondrogenic and endothelial cells. Preparations of the Zchm-1 can be placed in areas in need of bone or cartilage repair. Zchm-1 can also be administered to muscles or endothelial cells which are in need of repair. Instead of the polypeptide the Zchml gene can be administered as described below.
  • GENE THERAPY Polynucleotides encoding Zchml polypeptides are useful within gene therapy applications where it is desired to increase or inhibit Zchml activity. If a mammal has a mutated or absent Zchml gene, the Zchml gene can be introduced into the cells of the mammal . In one embodiment, a gene encoding a Zchml polypeptide is introduced in vivo in a viral vector. Such vectors include an attenuated or defective DNA virus, such as, but not limited to, herpes simplex virus (HSV) , papillomavirus, Epstein Barr virus (EBV) , adenovirus, adeno-associated virus (AAV), and the like.
  • HSV herpes simplex virus
  • EBV Epstein Barr virus
  • AAV adeno-associated virus
  • Defective viruses which entirely or almost entirely lack viral genes, are preferred.
  • a defective virus is not infective after introduction into a cell.
  • Use of defective viral vectors allows for administration to cells in a specific, localized area, without concern that the vector can infect other cells.
  • Examples of particular vectors include, but are not limited to, a defective herpes simplex virus 1 (HSV1) vector, Kaplitt et al . , Molec . Cell . Neurosci .
  • an attenuated adenovirus vector such as the vector described by Stratford-Perricaudet et al . , J. Clin .
  • a Zchml gene can be introduced in a retroviral vector, e . g. , as described in
  • the vector can be introduced by lipofection in vivo using liposomes.
  • Synthetic cationic lipids can be used to prepare liposomes for in vivo transfection of a gene encoding a marker, Feigner et al . , Proc. Natl . Acad.
  • lipofection to introduce exogenous genes into specific organs in vivo has certain practical advantages.
  • Molecular targeting of liposomes to specific cells represents one area of benefit. More particularly, directing transfection to particular cells represents one area of benefit. For instance, directing transfection to particular cell types would be particularly advantageous in a tissue with cellular heterogeneity, such as the pancreas, liver, kidney, and brain.
  • Lipids may be chemically coupled to other molecules for the purpose of targeting.
  • Targeted peptides e . g. , hormones or neurotransmitters
  • proteins such as antibodies, or non-peptide molecules can be coupled to liposomes chemically.
  • DNA vectors for gene therapy can be introduced into the desired host cells by methods known in the art, e . g. , transfection, electroporation, microinjection, transduction, cell fusion, DEAE dextran, calcium phosphate precipitation, use of a gene gun or use of a DNA vector transporter. See, e. g. , Wu et al . , J. Biol . Chem . 267 : 963 (1992); Wu et al . , J " . Biol . Chem . 263 : 14621 -4 , 1988.
  • Antisense methodology can be used to inhibit Zchml gene transcription, such as to inhibit cell proliferation in vivo.
  • Polynucleotides that are complementary to a segment of a Zchml-encoding polynucleotide e . g. , a polynucleotide as set froth in SEQ
  • ID NO:l are designed to bind to Zchml-encoding mRNA and to inhibit translation of such mRNA.
  • antisense polynucleotides are used to inhibit expression of Zchml polypeptide-encoding genes in cell culture or in a subject .
  • the present invention also provides reagents which will find use in diagnostic applications.
  • the Zchml gene a probe comprising Zchml DNA or RNA or a subsequence thereof can be used to determine if the Zchml gene is present on chromosome llpl5.4 or if a mutation has occurred.
  • Detectable chromosomal aberrations at the Zchml gene locus include, but are not limited to, aneuploidy, gene copy number changes, insertions, deletions, restriction site changes and rearrangements.
  • Such aberrations can be detected using polynucleotides of the present invention by employing molecular genetic techniques, such as restriction fragment length polymorphism (RFLP) analysis, short tandem repeat (STR) analysis employing PCR techniques, and other genetic linkage analysis techniques known in the art (Sambrook et al . , ibid. ; Ausubel et . al . , ibid. ; Marian, Chest 108 : 255
  • Transgenic mice engineered to express the Zchml gene, and mice that exhibit a complete absence of Zchml gene function, referred to as "knockout mice", Snouwaert et al . , Science 257:1083 (1992), may also be generated, Lowell et al . , Nature 366: 740 -42 (1993). These mice may be employed to study the Zchml gene and the protein encoded thereby in an in vivo system.
  • Radiation hybrid mapping is a somatic cell genetic technique developed for constructing high- resolution, contiguous maps of mammalian chromosomes (Cox et al . , Science 250 : 245 (1990). Partial or full knowledge of a gene's sequence allows one to design PCR primers suitable for use with chromosomal radiation hybrid mapping panels. Radiation hybrid mapping panels are commercially available which cover the entire human genome, such as the Stanford G3 RH Panel and the GeneBridge 4 RH Panel (Research Genetics, Inc., Huntsville, AL) . These panels enable rapid, PCR-based chromosomal localizations and ordering of genes, sequence-tagged sites (STSs) , and other nonpolymorphic and polymorphic markers within a region of interest.
  • STSs sequence-tagged sites
  • the precise knowledge of a gene ' s position can be useful for a number of purposes, including: 1) determining if a sequence is part of an existing contig and obtaining additional surrounding genetic sequences in various forms, such as YACs, BACs or cDNA clones; 2) providing a possible candidate gene for an inheritable disease which shows linkage to the same chromosomal region; and 3) cross-referencing model organisms, such as mouse, which may aid in determining what function a particular gene might have.
  • ZChm-1 was mapped to chromosome llpl5.4 region.
  • Sequence tagged sites can also be used independently for chromosomal localization.
  • An STS is a
  • An STS is defined by a pair of oligonucleotide primers that are used in a polymerase chain reaction to specifically detect this site in the presence of all other genomic sequences.
  • STSs are based solely on DNA sequence they can be completely described within an electronic database, for example, Database of Sequence Tagged Sites (dbSTS) , GenBank, (National Center for Biological Information, National Institutes of Health, Bethesda, MD http://www.ncbi.nlm.nih.gov), and can be searched with a gene sequence of interest for the mapping data contained within these short genomic landmark STS sequences .
  • dbSTS Database of Sequence Tagged Sites
  • the proteins of the present invention are formulated for parenteral , particularly intravenous or subcutaneous, delivery according to conventional methods. Intravenous administration will be by bolus injection or infusion over a typical period of one to several hours.
  • pharmaceutical formulations will include a Zchml protein in combination with a pharmaceutically acceptable vehicle, such as saline, buffered saline, 5% dextrose in water or the like. Formulations may further include one or more excipients, preservatives, solubilizers, buffering agents, albumin to prevent protein loss on vial surfaces, etc. Methods of formulation are well known in the art and are disclosed, for example, in Remington: The Science and
  • Therapeutic doses will generally be in the range of 0.1 to 100 ⁇ g/kg of patient weight per day, preferably 0.5-20 mg/kg per day, with the exact dose determined by the clinician according to accepted standards, taking into account the nature and severity of the condition to be treated, patient traits, etc. Determination of dose is within the level of ordinary skill in the art .
  • the proteins may be administered for acute treatment, over one week or less, often over a period of one to three days or may be used in chronic treatment, over several months or years. In particular these preparations can be used to promote bone or cartilage repair.
  • the polynucleotides provided by the present invention can be used by the research community for various purposes.
  • the polynucleotides can be used to express recombinant protein for analysis, characterization or therapeutic; as markers for tissues in which the corresponding protein is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or disease states) ; as molecular weight markers on Southern gels; as chromosome markers (when labeled) to map related gene positions; to compare with endogenous DNA sequences in patients to identify potential genetic disorders; as probes to hybridize and thus discover novel, related DNA sequences; as a source of information to derive PCR primers for genetic fingerprinting; as a probe to "subtract-out" known sequences in the process of discovering other novel polynucleotides; to raise anti-protein antibodies using DNA immunization techniques; and as an antigen to raise anti-DNA antibodies or elicit another immune response.
  • the polynucleotide encodes a protein which binds or potentially binds to another protein (such as, for example, in a receptor-ligand interaction)
  • the polynucleotide can also be used in interaction trap assays [such as, for example, that described in Gyuris et al .
  • the proteins provided by the present invention can similarly be used to raise antibodies or to elicit another immune response: as a reagent (including the labeled reagent) in assays designed to quantitatively determine levels of the protein (or its receptor) in biological fluids; as markers for tissues using labeled antibodies; and to isolate correlative receptors or ligands.
  • a reagent including the labeled reagent
  • the protein can be used to identify the other protein with which binding occurs or to identify inhibitors of the binding interaction. Proteins involved in these binding interactions can also be used to screen for peptide or small molecule inhibitors or agonists of the binding interaction.
  • a protein of the present invention may exhibit cytokine-cell proliferation (either inducing or inhibiting) or cell differentiation (either inducing or inhibiting) activity or may induce production of other cytokines in certain cell populations.
  • cytokine-cell proliferation either inducing or inhibiting
  • cell differentiation either inducing or inhibiting
  • the activity of a protein of the present invention is evidenced by any one of a number of routine factor dependent cell proliferation assays for cell lines including without limitation, 32D, DA2 , DA1G, T10, B9, B9/11, BaF3, MC9/G, M+ (preB M+) , 2E8, RB5, DAI, 123, T1165, HT2, CTLL2, TF-1, Mo7e and CMK.
  • the activity of a protein of the invention may, among other means, be measured by assays for T-cell or thymocyte proliferation, assays for cytokine production or proliferation of spleen cells, lymph node cells or thymocytes, assays for proliferation and differentiation of hematopoietic and lymphopoietic cells, and assays for T-cell clone responses to antigens which will identify, among others, proteins that affect antigen-presenting cells (APC) /T-cell interactions as well as direct T-cell effects by measuring proliferation and cytokine production.
  • APC antigen-presenting cells
  • immunological assays include assays for T-cell dependent immunoglobulin responses and isotype switching (which will identify, among others, proteins that modulate T-cell dependent antibody responses and that affect Thl/Th2 profiles) ; mixed lymphocyte reaction (MLR) assays (which will identify proteins that generate predominantly Thl and CTL responses) ; dendritic cell- dependent assays (which will identify, among others, proteins expressed a by dendritic cells that activate na ⁇ ve T-cells) ; assays for lymphocyte survival/apoptosis (which will identify proteins that prevent apoptosis after superantigen induction and proteins that regulate lymphocyte homeostasis) ; assays for B cell function and assays for protein that influence early steps of T-cell commitment and development.
  • MLR mixed lymphocyte reaction
  • dendritic cell- dependent assays which will identify, among others, proteins expressed a by dendritic cells that activate na ⁇ ve T-cells
  • a protein of the present invention may also exhibit immune stimulating or immune suppressing activity including, without limitation, the activities for which assays are described herein.
  • a protein may be useful in the treatment of various immune deficiencies and disorders [including severe combined immunodeficiency (SCIC) ] , e . g. , in regulating (up or down) growth and proliferation of T or B lymphocytes., as well as effecting the cytolytic activity of natural killer (NK) cells and other cell populations.
  • SCIC severe combined immunodeficiency
  • NK natural killer
  • These immune deficiencies may be genetic or by caused by viral as well as bacterial or fungal infections or may result from autoimmune disorders.
  • the protein of the present invention by may possibly be used to treat such diseases or to boost the immune system.
  • the protein of the present invention may be useful in promoting hematopoiesis, including causing proliferation of red blood cells, megakaryocytes, and myeloid cells such as monocytes/macrophages .
  • Assays for relating to stem cell growth or differentiation include: Freshney, M.G., in Culture of Hematopoietic Cells, Frshney, R.I. et al., Eds . (Wiley-Liss, Inc., New York, N.Y., 1994); Johansson et al . Cell . Bio . 15:141-151 (1995); Keller et al . , Mol . & Cell . Bio . 13:473-486 (1993); McClanahan et al .
  • the protein of the present invention may be used to repair or regenerate any number of different tissues including bone, ligaments, tendons, neurons and skin.
  • Assays for tissue regeneration include those described in International Patent Publication No. WO95/16035 (bone, cartilage, tendon) ; WO95/05846 (neuron) ; and WO91/07491 (skin, endothelium) .
  • a protein of the present invention may also exhibit activin or inhibin related activities.
  • Inhibin is a glycoprotein that circulates in plasma and inhibits gonadotropin-releasing hormone (GnRH) -stimulated follicle stimulating hormone (FSH) secretion by the pituitary gland.
  • GnRH gonadotropin-releasing hormone
  • FSH follicle stimulating hormone
  • the protein of the present invention may be useful as a contraceptive or as a based upon the ability of inhibins to decrease fertility in female mammals and decrease spermatogenesis in male mammals.
  • Assays for activin/inhibin activity are described in the following: Vale et al . , Endocrinology 91:562-572 (1972); Ling et al . , Nature 321 : 779-782 (1986); Vale et al . ,
  • Zchml cDNA was discovered in a mesentery tumor, sigmoid, mets mixed-mullerian tumor cDNA library.
  • the library was constructed using 1 microgram of polyA RNA isolated from sigmoid mesentery tumor tissue removed from a 61-year-old female during a total abdominal hysterectomy and bilateral salpingo-oophorectomy with regional lymph node excision.
  • Pathology indicated a metastatic grade 4 malignant mixed mullerian tumor present in the sigmoid mesentery at two sites. This tumor was associated with a grade 4 malignant mixed-mullerian tumor, heterologous type, of the uterus, forming a firm, infiltrating mass throughout the yometrium and involving the serosal surface.
  • the heterologous elements of the tumor consisted of rhabdomyoblasts and immature cartilage.
  • the tumor also involved the lower uterine segment and extended into the cervical wall.
  • Extensive lymphatic and vascular permeation was identified in the myometrium and cervical wall .
  • One (of 7) right common iliac and one (of 7) right external iliac lymph nodes were identified with metastatic grade 4 malignant mixed mullerian tumor, with the metastases comprised mainly of adenocarcinoma .
  • cDNA synthesis was initiated using a Notl-oligo (dT) primer.
  • Double-stranded cDNA was blunted, ligated to EcoRI adaptors, digested with NotI, size-selected, and cloned into the Notl and EcoRI sites a plasmid.
  • Expressed sequence tags (EST) from the cDNA library were scanned to discover sequences having homology to the chondromodulin gene.
  • the EST of SEQ ID NO: 15 was discovered and the clone obtained and sequenced resulting in the Zchml gene of SEQ ID NO:l.
  • the open reading frame of Zchm-1 was subcloned into vector pZP9CEE for expression in mammalian cells.
  • the pZP9CEE was the pZP9 (ATCC 98668) into which DNA encoding a glu-glu epitope tag was inserted. See Grussenmeyer, T. et al . , Proc Na tl Acad Sci .
  • the polymerase chain reaction was carried out in a reaction containing 10 ⁇ l of native Pfu DNA polymerase buffer, 1 ⁇ l of a deoxynucleotide triphosphate solution containing 10 mM each of dATP, dGTP, dTTP and dCTP (Pharmacia LKB Biotechnology Inc., Piscataway, NJ) , 5 ⁇ l of 7 pmole/ ⁇ l primer ZC18149 (SEQ ID NO:7), 5 ⁇ l of 7 pmole/ ⁇ l primer ZC18150 (SEQ ID NO: 8), 74 ⁇ l of water, 3 ⁇ l of 10 ng/ ⁇ l Xho I digested pSLZchml -3 template, a plasmid which contained the Zchm-1 cDNA, and 2 ⁇ l of 2.5 U/ ⁇ l native Pfu DNA polymerase (Stratagene Clon
  • the polymerase chain reaction was run for 13 cycles (20 seconds at 95° C and 1.5 minutes at 72° C) followed by a 5 minute incubation at 72° C.
  • the amplified products were serially extracted with phenol/chloroform, chloroform and precipitated with ethanol in the presence of PELLET PAINT ® carrier (Invitrogen, Carlsbad, CA) and 0.3 M sodium acetate.
  • the pellet was re-suspended in 10 ⁇ l water to which was added 4 ⁇ l of 2X TANGO ® buffer (MBI Fermentas, Inc.) and 1 ⁇ l of 10 U/ ⁇ l Sal I (MBI Fermentas) . Digestion was carried out a 37° C for 30 minutes.
  • HI MBI Fermentas, Inc.
  • Digestion was carried out at 37° C for 30 minutes.
  • the reaction was terminated by extraction with phenol and chloroform followed by ethanol precipitation in the presence of 0.3 M sodium acetate.
  • the isolated cDNA inserts described above were ligated into Xho I and Bam HI digested and dephosphorylated pZP9CEE vector.
  • the ligated DNA was transfected into MAXIMUM EFFICIENCY DH10B ® competent cells
  • the resultant plasmid pSLZchml -8 encodes full-length native Zchm-1 polypeptide .
  • a Glu tag was added to the C-terminal of Zchm-1.
  • the native Zchm-1 termination codon was removed by sited directed mutagenesis allowing the production of an inframe fusion of the Zchm-1 C-terminus to a Glu affinity tag encoded by pZPCEE vector sequences.
  • a cDNA fragment encoding the mutagenized Zchm-1 coding sequence was obtained by polymerase chain reaction from 30 ng of Xho I digested pSLZchml 03 template employing 5' primer SEQ
  • SEQ ID NO : 9 incorporate a Sal I and Bam HI restriction site, respectively.
  • the conditions for polymerase chain reaction and cloning into pZP9CEE are identical to that described above for the construction of pSLZChml -8.
  • the resulting plasmid, pSLZChmlCT - 1 encodes full-length Zchm-
  • Northern blot analysis shows a 1.4 kb Zchm-1 transcript present in poly A mRNA samples purified from skeletal muscle and bone marrow.
  • the Zchm-1 locus is mapped to chromosome llpl5. 4 . It was mapped to chromosome 11 using the
  • GeneBridge 4 Radiation Hybrid Panel (Research Genetics, Inc. , Huntsville, AL) .
  • the GeneBridge 4 Radiation Hybrid Panel contains PCR amplifiable DNAs from each of 93 radiation hybrid clones, plus two control DNAs (the HFL donor and the A23 recipient) .
  • a publicly available WWW server http : //www-genome . wi .mit . edu/cgi- bin/contig/rhmapper .pi) allows mapping relative to the Whitehead Institute/MIT center for Genome Research's radiation hybrid map of the human genome (the "WICGR" radiation hybrid map) which was constructed with the GeneBridge 4 Radiation Hybrid Panel.
  • the reactions were overlaid with an equal amount of mineral oil and sealed.
  • the PCR cycler conditions were as follows: an initial 1 cycle 5 minute denaturation at 95° C, 40 cycles of a 1 minute denaturation at 95° C, 1 minute annealing at 66° C and 1.5 minute extension at 72° C, followed by a final 1 cycle extension of 7 minutes at 72°C.
  • the reactions were separated by electrophoresis on a 2% agarose gel (Life Technologies, Inc., Gaithersburg, MD) .

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des molécules de polynucléotides et de polypeptides destinées à un polypeptide de type chondromoduline de mammifère.
PCT/US1999/026909 1998-11-13 1999-11-12 Proteine de type chondromoduline de mammmifere WO2000029579A1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
IL14305299A IL143052A0 (en) 1998-11-13 1999-11-12 Mammalian chondromodulin-like protein
JP2000582562A JP2002530078A (ja) 1998-11-13 1999-11-12 哺乳動物のコンドロモジュリン様タンパク質
CA002350623A CA2350623A1 (fr) 1998-11-13 1999-11-12 Proteine de type chondromoduline de mammmifere
EP99958955A EP1131427A1 (fr) 1998-11-13 1999-11-12 Proteine de type chondromoduline de mammmifere
AU16222/00A AU1622200A (en) 1998-11-13 1999-11-12 Mammalian chondromodulin-like protein

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19198698A 1998-11-13 1998-11-13
US09/191,986 1998-11-13

Publications (1)

Publication Number Publication Date
WO2000029579A1 true WO2000029579A1 (fr) 2000-05-25

Family

ID=22707752

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/026909 WO2000029579A1 (fr) 1998-11-13 1999-11-12 Proteine de type chondromoduline de mammmifere

Country Status (7)

Country Link
EP (1) EP1131427A1 (fr)
JP (1) JP2002530078A (fr)
AU (1) AU1622200A (fr)
CA (1) CA2350623A1 (fr)
IL (1) IL143052A0 (fr)
WO (1) WO2000029579A1 (fr)
ZA (1) ZA200103699B (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001023557A1 (fr) * 1999-09-29 2001-04-05 Teijin Limited Polypeptides et genes les codant
WO2001048203A1 (fr) * 1999-12-27 2001-07-05 Takeda Chemical Industries, Ltd. Nouvelle proteine et adn associe
WO2001053344A2 (fr) * 2000-01-19 2001-07-26 Amgen, Inc. Peptide apparente a la chondromoduline-i
EP1144614A2 (fr) * 1999-01-19 2001-10-17 Human Genome Sciences, Inc. Proteines humaines secretees (33)
EP1374888A1 (fr) * 2001-02-28 2004-01-02 Mitsubishi Pharma Corporation Remedes pour l'arthrite deformante et pour l'arthrite rhumatoide
WO2006021942A2 (fr) * 2004-08-26 2006-03-02 Royal College Of Surgeons In Ireland Peptides bioactifs
EP1681302A1 (fr) * 2003-10-21 2006-07-19 Teijin Pharma Limited Nouvelle proteine, son procede de production et son utilisation
US8481676B2 (en) 2003-10-21 2013-07-09 Teijin Pharma Limited Protein and production process and use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999053051A2 (fr) * 1998-04-09 1999-10-21 Genset Etiquettes de sequences exprimees (est) des 5' et proteines humaines codees

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999053051A2 (fr) * 1998-04-09 1999-10-21 Genset Etiquettes de sequences exprimees (est) des 5' et proteines humaines codees

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ADAMS M. D. ET AL.: "Initial assessment of human gene diversity and expression patterns based upon 83 million nucleotides of cDNA sequence.", EMBL DATABASE ENTRY HSZZ02372; ACCESSION NUMBER AA297231, 18 April 1997 (1997-04-18), XP002133438 *
HILLIER ET AL.: "WashU-Merck EST Project.", EMBL DATABASE ENTRY HS1154447; ACCESSION NUMBER AA236166, 6 March 1997 (1997-03-06), XP002133435 *
LIEW C. C. ET AL.: "A catalogue of genes in the cardiovascular system as identified by expressed sequence tags.", EMBL DATABASE ENTRY HS1807; ACCESSION NUMBER T12180, 18 December 1994 (1994-12-18), XP002133437 *
STRAUSBERG R.: "National Cancer Institute, Cancer Genome Anatomy Project.", EMBL DATABASE ENTRY AI123839; ACCESSION NUMBER AI123839, 8 September 1998 (1998-09-08), XP002133436 *

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1144614A2 (fr) * 1999-01-19 2001-10-17 Human Genome Sciences, Inc. Proteines humaines secretees (33)
EP1144614A4 (fr) * 1999-01-19 2003-08-06 Human Genome Sciences Inc Proteines humaines secretees (33)
US7575922B2 (en) 1999-09-29 2009-08-18 Teijin Limited Polypeptide and gene encoding the same
US8030277B2 (en) 1999-09-29 2011-10-04 Teijin Limited Polypeptide and gene encoding the same
WO2001023557A1 (fr) * 1999-09-29 2001-04-05 Teijin Limited Polypeptides et genes les codant
WO2001048203A1 (fr) * 1999-12-27 2001-07-05 Takeda Chemical Industries, Ltd. Nouvelle proteine et adn associe
WO2001053344A3 (fr) * 2000-01-19 2002-01-03 Amgen Inc Peptide apparente a la chondromoduline-i
WO2001053344A2 (fr) * 2000-01-19 2001-07-26 Amgen, Inc. Peptide apparente a la chondromoduline-i
EP1374888A4 (fr) * 2001-02-28 2004-07-07 Mitsubishi Pharma Corp Remedes pour l'arthrite deformante et pour l'arthrite rhumatoide
EP1374888A1 (fr) * 2001-02-28 2004-01-02 Mitsubishi Pharma Corporation Remedes pour l'arthrite deformante et pour l'arthrite rhumatoide
EP1681302A1 (fr) * 2003-10-21 2006-07-19 Teijin Pharma Limited Nouvelle proteine, son procede de production et son utilisation
EP1681302A4 (fr) * 2003-10-21 2007-06-13 Teijin Pharma Ltd Nouvelle proteine, son procede de production et son utilisation
AU2004282071B2 (en) * 2003-10-21 2010-11-18 Teijin Limited Novel protein and production process and use thereof
US8481676B2 (en) 2003-10-21 2013-07-09 Teijin Pharma Limited Protein and production process and use thereof
US8617841B2 (en) 2003-10-21 2013-12-31 Teijin Pharma Limited Protein and production process and use thereof
WO2006021942A2 (fr) * 2004-08-26 2006-03-02 Royal College Of Surgeons In Ireland Peptides bioactifs
WO2006021942A3 (fr) * 2004-08-26 2007-03-15 Royal College Of Surgeons Ie Peptides bioactifs

Also Published As

Publication number Publication date
AU1622200A (en) 2000-06-05
IL143052A0 (en) 2002-04-21
CA2350623A1 (fr) 2000-05-25
JP2002530078A (ja) 2002-09-17
EP1131427A1 (fr) 2001-09-12
ZA200103699B (en) 2001-11-14

Similar Documents

Publication Publication Date Title
US7084253B2 (en) Protease-activated receptor PAR4 (ZCHEMR2)
EP1131427A1 (fr) Proteine de type chondromoduline de mammmifere
AU7480198A (en) Novel tumor antigens
US7217790B2 (en) UMLR polypeptides
US6372889B1 (en) Soluble protein ZTMPO-1
WO1998055612A1 (fr) Precurseurs de neurokinine b
US7122342B1 (en) Protease-activated receptor PAR4 (ZCHEMR2)
WO2000028030A1 (fr) Proteine secretoire humaine 61
AU8286698A (en) Mammalian secretory peptide-9
MXPA01004743A (en) Mammalian chondromodulin-like protein
WO1998054326A1 (fr) Chemokine humaine zchemo-8
EP1144450A1 (fr) Proteine-12 a mammalienne helice alpha
MXPA01004744A (en) Human secretory protein-61
US20040058354A1 (en) Mammalian alpha-helical protein-53
WO2000071717A1 (fr) Proteine 32 alpha helicoidale secretee
WO2001000664A2 (fr) Proteine-36 en helice alpha secretee
WO1998044117A1 (fr) Chimiokine zsig-35 d'origine humaine
CA2321176A1 (fr) Homologues du facteur de croissance pour le tissu conjonctif
US20030207793A1 (en) Secreted alpha-helical protein - 32
EP1355937A2 (fr) Proteine-53 alpha helicoidale secretee par des mammiferes
US20050124801A1 (en) Mammalian secretory peptide - 9
EP1323823A2 (fr) Peptide de sécretion-9 de mammifère, anticorps correspondants et leur utilisation
AU5448700A (en) Secreted alpha-helical protein-31

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2000 16222

Country of ref document: AU

Kind code of ref document: A

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2001/03699

Country of ref document: ZA

Ref document number: 200103699

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 143052

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/004743

Country of ref document: MX

Ref document number: 511644

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2350623

Country of ref document: CA

Kind code of ref document: A

Ref document number: 2350623

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2000 582562

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 16222/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1999958955

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999958955

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1999958955

Country of ref document: EP